- Home
- PHAR vs WLDN Comparison
PHAR vs WLDN Comparison
Compare PHAR & WLDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- WLDN
- Stock Information
- Founded
- PHAR 1988
- WLDN 1964
- Country
- PHAR Netherlands
- WLDN United States
- Employees
- PHAR N/A
- WLDN N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- WLDN Military/Government/Technical
- Sector
- PHAR Health Care
- WLDN Consumer Discretionary
- Exchange
- PHAR Nasdaq
- WLDN Nasdaq
- Market Cap
- PHAR 1.0B
- WLDN 1.6B
- IPO Year
- PHAR N/A
- WLDN 2006
- Fundamental
- Price
- PHAR $14.27
- WLDN $100.58
- Analyst Decision
- PHAR Strong Buy
- WLDN Strong Buy
- Analyst Count
- PHAR 3
- WLDN 2
- Target Price
- PHAR $30.00
- WLDN $111.50
- AVG Volume (30 Days)
- PHAR 12.8K
- WLDN 452.1K
- Earning Date
- PHAR 10-23-2025
- WLDN 10-30-2025
- Dividend Yield
- PHAR N/A
- WLDN N/A
- EPS Growth
- PHAR N/A
- WLDN 94.22
- EPS
- PHAR N/A
- WLDN 2.39
- Revenue
- PHAR $339,836,000.00
- WLDN $628,172,000.00
- Revenue This Year
- PHAR $16.63
- WLDN N/A
- Revenue Next Year
- PHAR $6.77
- WLDN $9.00
- P/E Ratio
- PHAR N/A
- WLDN $42.04
- Revenue Growth
- PHAR 22.44
- WLDN 13.82
- 52 Week Low
- PHAR $7.31
- WLDN $30.43
- 52 Week High
- PHAR $17.08
- WLDN $121.00
- Technical
- Relative Strength Index (RSI)
- PHAR 54.65
- WLDN 48.78
- Support Level
- PHAR $13.63
- WLDN $96.14
- Resistance Level
- PHAR $15.61
- WLDN $106.22
- Average True Range (ATR)
- PHAR 0.93
- WLDN 5.19
- MACD
- PHAR -0.13
- WLDN -1.79
- Stochastic Oscillator
- PHAR 35.98
- WLDN 28.02
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About WLDN Willdan Group Inc.
Willdan Group Inc is a provider of professional technical and consulting services to utilities, private industry, and public agencies at all levels of government. It operates in the business segments of Energy and Engineering and Consulting. It generates the majority of its revenue from the Energy segment, which includes services such as audit and surveys, program design, master planning, benchmarking analysis, design engineering, construction management, performance contracting, installation, advances in software and data analytics, and other services. All of its revenue is derived from the domestic markets.